Mirati Therapeutics (NASDAQ:MRTX) has received mixed analyst ratings over the past quarter, with 11 analysts offering diverse opinions. The average 12-month price target for MRTX is $64.09, with a high estimate of $83.00 and a low of $58.00, reflecting a 7.34% increase from the previous target of $59.71. Analysts from Citigroup, Leerink Partners, Stifel, Piper Sandler, B. Riley Securities, Scotiabank, Jefferies, BMO Capital, and JMP Securities have adjusted their ratings and price targets, indicating a range of expectations for the company's performance. Mirati Therapeutics, a clinical-stage oncology company, has shown a revenue growth rate of 201.97% as of September 30, 2023, but struggles with a net margin of -987.22% and an ROA of -15.84%, despite a strong ROE of -19.33% and a low debt-to-equity ratio of 0.05.